c-RET
Les inhibiteurs de c-RET ciblent le proto-oncogène RET (Rearranged during Transfection), qui code une tyrosine kinase réceptrice impliquée dans la croissance, la différenciation et la survie cellulaire. L'activation anormale de la signalisation RET peut entraîner une prolifération cellulaire incontrôlée et une résistance à l'apoptose, contribuant au développement de cancers tels que le carcinome médullaire de la thyroïde et le cancer du poumon non à petites cellules. L'inhibition de c-RET peut induire l'apoptose dans les cellules cancéreuses et constitue une approche prometteuse dans la thérapie ciblée du cancer. Chez CymitQuimica, nous offrons une variété d'inhibiteurs de c-RET de haute qualité pour soutenir vos recherches en oncologie, transduction du signal et apoptose.
51 produits trouvés pour "c-RET"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS :BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Formule :C23H27F4N3O4SDegré de pureté :99.23%Couleur et forme :SolidMasse moléculaire :517.54RD-23
CAS :RD-23 is an orally active and selective RET PROTAC degrader. It facilitates the ubiquitination and degradation of the RETG810C mutant with a DC50 value of 11.7 nM. Additionally, RD-23 inhibits the activation of downstream Shc signaling and induces apoptosis (Apoptosis). It is useful for studying RET-related cancers.Formule :C52H56N12O4Couleur et forme :SolidMasse moléculaire :913.079AD57 (hydrochloride)
CAS :AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Formule :C22H21ClF3N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :491.9RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Couleur et forme :Odour SolidRET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Formule :C40H44N10OCouleur et forme :SolidMasse moléculaire :680.84QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Formule :C53H54N12O4Couleur et forme :SolidMasse moléculaire :923.07RET ligand-1
CAS :RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Formule :C28H24F2N6O3Couleur et forme :SolidMasse moléculaire :530.525Zeteletinib hemiadipate
CAS :Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Formule :C56H56F6N8O12Couleur et forme :SolidMasse moléculaire :1147.098RET-IN-4
CAS :RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Formule :C27H31FN10O2Couleur et forme :SolidMasse moléculaire :546.611PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formule :C22H22FN5O2Couleur et forme :SolidMasse moléculaire :407.44Compound TPX-0046
CAS :Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Formule :C21H21FN6O3Degré de pureté :99.94%Couleur et forme :SoildMasse moléculaire :424.43RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Formule :C38H42N10O3Couleur et forme :SolidMasse moléculaire :686.81YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Formule :C58H63F3N12O9Couleur et forme :SolidMasse moléculaire :1129.19BT44
CAS :BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Formule :C28H27F4N3O4SDegré de pureté :99.87%Couleur et forme :SoildMasse moléculaire :577.59trans-Pralsetinib
CAS :trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).Formule :C27H32FN9O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :533.6Pralsetinib
CAS :Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFormule :C27H32FN9O2Degré de pureté :97.88% - 99.8%Couleur et forme :SolidMasse moléculaire :533.6WHI-P180
CAS :WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Formule :C16H15N3O3Degré de pureté :99.21%Couleur et forme :SolidMasse moléculaire :297.31SPP-86
CAS :SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Formule :C16H15N5Degré de pureté :99.53%Couleur et forme :SolidMasse moléculaire :277.32Pyrazoloadenine
CAS :Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.Formule :C5H5N5Degré de pureté :99.02%Couleur et forme :Beige PowderMasse moléculaire :135.13WHI-P180 hydrochloride
CAS :WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.Formule :C16H16ClN3O3Couleur et forme :SolidMasse moléculaire :333.77
